OBJECTIVE: To investigate the effects of 24 months of @entity11347 treatment on the endometrium in postmenopausal @entity1 . DESIGN: An open, prospective, multicenter study with a treatment duration of 24 months. POPULATION: One hundred and fifty healthy postmenopausal @entity1 . METHODS: @entity1 were treated with one tablet of @entity11347 (2.5 mg Org OD14) daily. Endometrial biopsies were taken at baseline, 12 months (n = 112) and 24 months (n = 62) to investigate endometrial histology by means of light microscopy. RESULTS: No stimulation of @entity3202 endometrium was observed in 98.2% and 91.9% of the analyzed @entity1 after 12 and 24 months, respectively. A change from an @entity3202 endometrial pattern to a weakly proliferative pattern was seen in 1.8% (95% confidence interval (CI) 0.22-6.45) and 6.5% (95% CI 1.20-7.51) of the @entity1 after 12 and 24 months, respectively. In one @entity1 , the endometrial pattern after 24 months was classified as simple @entity1373 (1.6%; 95% CI 0.01-3.20). The low incidence of proliferation and/or @entity1373 corresponds to that seen in other clinical trials in which @entity1 have been treated with placebo. @entity3556 and/or spotting was reported by 18 @entity1 (12%), all showing an @entity3202 endometrium at all assessments, except for one @entity1 with a proliferative endometrium at 24 months. CONCLUSION: In the majority of @entity1 (92%), the endometrium remained @entity3202 during 24 months of @entity11347 treatment.

Effects of XXXX on the endometrium.

@entity1 :: ('9606', 'Species') :: ['women', 'woman', 'Women'] @entity3556 :: ('MESH:D014592', 'Disease') :: ['Vaginal bleeding'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia'] @entity3202 :: ('MESH:D016109', 'Disease') :: ['atrophic'] @entity11347 :: ('MESH:C027385', 'Chemical') :: ['tibolone']
@entity11347 :: (MESH:C027385,Chemical) :: ['tibolone']
